Исследование минимальной остаточной болезни у детей с острым лимфобластным лейкозом из в-линейных предшественников, получающих терапию по протоколам ALL-MB 2008 и MLL-BABY, методом проточной цитометри
Диссертация
При сравнении экспрессии различных антигенов нормальными и опухолевыми клетками, нами были выявлены существенные отличия бластов при ВП-ОЛЛ как от зрелых B-лимфоцитов, так и от нормальных ВП по уровню экспрессии CD 10, CD45, CD20, CD58 и CD38. В то же время экспрессия CD34 опухолевыми клетками достоверно не отличалась от экспрессии данного антигена ВП. Все исследованные маркеры применимы для… Читать ещё >
Список литературы
- Азовская, Т.Ю. Клинико-иммунологическая характеристика острых лейкозов у детей Уральского региона: Автореф. канд. Мед. Наук. / Т.Ю. Азовская- ГНЦ Институт иммунологии Минздрава России. — М., 1998. — 27 с.
- Белевцев, М.В. Определение остаточных опухолевых клеток в костном мозге детей с B-линейным острым лимфобластным лейкозом методом проточной цитофлюорометрии / М. В. Белевцев, В. П. Савицкий, H.H. Савва и др. // Клин. Лаб. Диагн. 2006. — № 10. — С. 42−46.
- Клиническая онкогематология / Под ред. М. А. Волковой — М: Медиина, 2007.-1120 с.
- Руководство по гематологии. В 3-х т. Т. 1 / Под ред. А. И. Воробьева М: Ньюдиамед, 2002. — 280 с.
- Глузман Д.Ф. Диагностика лейкозов. Атлас и практическое руководство. / Д. Ф. Глузман, И. В. Абраменко, Л. М. Скляренко и др. Киев: Морион, 2000. — 224 с.
- Глузман Д.Ф. Диагностическая иммуноцитохимия опухолей. / Д. Ф. Глузман, И.В. Л. М. Скляренко В.А. Надгорная, И. А. Крячок. Киев: Морион, 2003.- 156 с.
- Ланцковский, Ф. Детская гематология и онкология / Ф. Ланцковский. М.: Лори, 2005. — 766 с.
- Луговская, С.А. Иммунофенотипирование в диагностике гемобластозов / С. А. Луговская, М. Е. Почтарь, H.H. Тупицын. М.: «Триада», 2005.- 167 с.
- Румянцева, Ю.В. Оптимизация терапии острого лимфобластного лейкоза у детей в России и Белоруссии: стратегия Москва-Берлин / Ю. В. Румянцева, А. И. Карачунский // Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2007. — № 4. — С. 13−22.
- Румянцева, Ю.В. Оптимизация терапии острого лимфобластного лейкоза у детей в России / Ю. В. Румянцева, А. И. Карачунский, А. Г. Румянцев // Педиатрия. 2009. — № 4. — С. 19−27.
- Фукс, О.Ю. Ранний ответ на терапию при использовании ПЭГ-аспарагиназы в циторедуктивной фазе лечения острого лимфобластного лейкоза / О. Ю. Фукс, К. Л. Кондратчик, Н. В. Мякова и др. // Гематология и траснфузиология. 2007. — № 6. — С. 22−26.
- Хоффбранд, В. Гематология. Атлас-справочник. / В. Хоффбранд, Дж. Петтит. М.: Практика, 2007.-408с.
- Цаур, Г. А. Время достижения молекулярной ремиссии как фактор прогноза у детей первого года жизни с острым лимфобластным лейкозом / Г. А. Цаур, Т. В. Наседкина, А. М. Попов и др. // Онкогематология. 2010. — № 2. — С. 46−54.
- Шориков, Е.В. Результаты программного лечения острого лимфобластного лейкоза у детей первого года жизни: Автореф. Канд. Мед. Наук. / Е.В. Шориков- НИИ Детской гематологии Минздрава России. М., 2005.-39 с.
- Armstrong, S.A. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia / S.A. Armstrong, J.E. Staunton, L.B. Silverman et al // Nat. Genetics. 2002. — Vol. 30, — P. 41−47.
- Basso, G. The role of immunophenotype in acute lymphoblastic leukemia of infant age / G. Basso, R. Rondelli, A. Covezzoli, M. Putti // Leuk. Lymphoma. 1994.-Vol. 15,-P. 51−60.
- Basso, G. New methodologic approaches for immunophenotyping acute leukemias / G. Basso, B. Buldini, L. De Zen, A. Orfao // Haematologica. 2001. -Vol. 86-P. 675−692.
- Basso, G. Diagnosis and genetic subtypes of leukemia combining gene expression and flow cytometry / G. Basso, C. Case, M. Campo Dell’Orto // Blood cells, molecules and diseases. 2007. — Vol. 39, N2. — P. 164−168.
- Basso, G. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow / G. Basso, M. Veltroni, M.G. Valsecchi et al // J. Clin. Oncol. 2009. — Vol. 27,-P. 5168−5174.
- Beillard, E. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR)-a Europe Against Cancer
- Program / E. Beillard, N. Pallisgaard, V.H.J, van der Velden et al // Leukemia. -2003.-Vol. 17, N1.-P. 1−13.
- Bene, M.C. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL) / M.C. Bene, G. Castoldi, W. Knapp et al // Leukemia. 1995. — Vol. 9, N 10. -P. 1783−1786.
- Bene, M.C. How and why minimal residual disease studies are necessary in leukemia: a review from WP10 and WP12 of the European LeukemiaNet / M.C. Bene, J.S. Kaeda // Haematologica. 2009. — Vol. 94, N8. — P. 1135−1150.
- Bhojwani, D. High-risk childhood acute lymphoblastic leukemia / D. Bhojwani, S.C. Howard, C.-H. Pui // Clin. Lymphoma Myeloma. 2009. — Vol. 9, Supp. 3.-P. S222-S230.
- Biondi, A. Role of treatment intensification in infants with acute lymphoblastic leukemia: results of two consecutive AIEOP studies / A. Biondi, C. Rizzari, M.G. Valsecchi et al // Haematologica. 2006. — Vol. 91, — P. 534−537.
- Bonney, G.E. Logistic regression for dependent binary observations / G.E. Bonney//Biometrics. 1987. — Vol. 43.-P. 951−973.
- Borkhardt, A. Molecular analysis of MLL/AF4 recombination in infant acute lymphoblastic leukemia / A. Borkhardt, R. Repp, E. Haupt et al // Leukemia. -1994. Vol. 8, N4. — P. 549−553.
- Borkhardt, A. Infant acute lymphoblastic leukemia combined cytogenetic, immunophenotypical and molecular analysis of 77 cases / A. Borkhardt, C. Wuchter, S. Viehmann et al // Leukemia. — 2002. — Vol. 16, — P. 1685−1690.
- Borowitz, M.J. Minimal residual disease detection in childhood ALL / M.J. Borowitz //Haematopoiesis Immunology. 2010. — Vol. 7, N1. — P. 24−35.
- Campana, D. The immunologic detection of minimal residual disease in acute leukemia / D. Campana, E. Coustan-Smith, G. Janossy // Blood. 1990. — Vol. 76, N1.-P. 163−171.
- Campana, D. Detection of minimal residual disease in acute leukaemia: methodologic advances and clinical significance / D. Campana, C.-H. Pui // Blood. — 1995.-Vol. 85, N6.-P. 1416−1434.
- Campana, D. Detection of minimal residual disease in acute leukaemia by flow cytometry / D. Campana, E. Coustan-Smith // Cytometry. 1999. — Vol. 38, N8.-P. 139−152.
- Campana, D. Advances in the immunological monitoring of childhood acute lymphoblastic leukaemia / D. Campana, E. Coustan-Smith // Best practice & clinical research haematology. 2002. — Vol. 15, N1. — P. 1−19.
- Campana, D. Determination of minimal residual disease in leukaemia patients / D. Campana // Br. J. Haematol. 2003. — Vol. 121, — P. 823−838.
- Campana, D. Minimal residual disease studies by flow cytometry in acute leukaemia / D. Campana, E. Coustan-Smith // Acta Haematol. 2004. — Vol. 112, N1−2.-P. 8−15.
- Campana, D. Minimal residual disease studies in acute leukaemia / D. Campana // Am. J. Clin. Pathol. 2004. — Vol. 122, — P. S47-S57.
- Campana, D. Progress of minimal residual disease studies in childhood acute leukemia / D. Campana // Curr. Hematol. Malig. Rep. 2010. — Vol. 5, N3. — P. 169−176.
- Cazzaniga, G. Monitoring of minimal residual disease in leukemia, advantages and pitfalls / G. Cazzaniga, G. Gaipa, V. Rossi, A. Biondi // Ann. Med. -2006.-Vol. 38,-P. 512−521.
- Chen, J.S. Identification of novel markers for monitoring minimal residual disease in acute lymphoblastic leukaemia / J.S. Chen, E. Coustan-Smith, T. Suzuki et al // Blood. 2001. — Vol. 97, N7. — P. 2115−2120.
- Chen, T. Application of triple-color flow cytometry for minimal residual disease detection in acute B-lymphoblastic leukemia / T. Chen, Y. Zhu, X. Zhou et al // Zhonghua Xue Ye Xue Za Zhi. 2001. — Vol. 22, N1. — P. 20−23.
- Chen, W. Stability of leukemia-associated immunophenotypes in precursor B-lymphoblastic leukemia/lymphoma: a single institution experience / W. Chen, N.J. Karandikar, R.W. McKenna, S.H. Kroft // Am. J. Clin. Pathol. 2007. -Vol.127, N1.-P. 39−46.
- Ciudad, J. Immunophenotypic analysis of CD 19+ precursors in normal human adult bone marrow: implications for minimal residual disease detection / J. Ciudad, A. Orfao, B. Vidriales et al // Haematologica. 1998. — Vol. 83, N12. — P. 1069−1075.
- Coustan-Smith, E. Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia / E. Coustan-Smith, F.G. Behm, J. Sanchez et al // Lancet. 1999. — Vol. 21, N2. — P. 550−554.
- Coustan-Smith, E. Clinical importance of minimal residual disease in children with acute lymphoblastic leukaemia / E. Coustan-Smith, J. Sancho, M.L. Hancock et al // Blood. 2000. — Vol. 96, N8. — P. 2691−2696.
- Coustan-Smith, E. Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukaemia / E. Coustan-Smith, J. Sancho, F.G. Behm et al // Blood. 2002. — Vol. 100, N1. — P. 5258.
- Coustan-Smith, E. Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukaemia / E.
- Coustan-Smith, J. Sancho, M.L. Hancock et al I I Blood. 2002. — Vol. 100, N7. — P. 2399−2402.
- Coustan-Smith, E. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse / E. Coustan-Smith, A. Gajjar, N. Hijiya et al // Leukemia. 2004. — Vol. 18, N3. — P. 499−504.
- Coustan-Smith, E. A simplified flow cytometric assay identifies children with acute lymphoblastic leukemia who have a superior clinical outcome / E. Coustan-Smith, R.C. Ribeiro, P. Stow et al. // Blood. 2006. — Vol. 108, N1. — P. 97 102.
- Craig, F.E. Flow cytometric immunophenotyping for hematologic neoplasms / F.E. Craig, K.A. Foon //Blood. 2008. — Vol. 111, N8. — P. 3941−3967.
- Cutrona, G. CD 10 is a marker for cycling cells with propensity to apoptosis in childhood ALL / G. Cutrona, P. Tasso, M. Dono et al // Brit. J. Cancer. -2002. Vol. 86, — P. 1776−1785.
- DeLong, E.R. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach / E.R. DeLong, D.M. DeLong, D.L. Clarke-Pearson // Biometrics. 1988. — Vol. 44. — P. 837−845.
- Demidenko, E. Sample size and optimal design for logistic regression with binary interaction / E. Demidenko // Stat. Med. 2008. — Vol. 27. — P. 36−46.
- De Zen, L. Quantitative multiparametric immunophenotyping in acute lymphoblastic leukemia: correlation with specific genotype. I. ETV6/AML1 ALLs identification / L. De Zen, A. Orfao, G. Cazzaniga et al // Leukemia. 2000. — Vol. 14.-P. 1225−1231.
- De Zen, L. Computational analysis of flow-cytometry antigen expression profiles in childhood acute lymphoblastic leukemia: an MLL/AF4 identification / L. De Zen, S. Bicciato, G. Te Cronie, G. Basso // Leukemia. 2003. — Vol. 17. — P. 1557−1565.
- DiGiuseppe, J.A. Overexpression of CD49f in precursor B-cell acute lymphoblastic leukemia: potential usefulness in minimal residual disease detection /
- J.A. DiGiuseppe, S.G. Fuller, MJ. Borowitz // Cytometry B Clin. Cytom. 2009. -Vol. 76B.-P. 150−155.
- Dworzak, M.N. Flow cytometric assessment of human MIC2 expression in bone marrow, thymus and peripheral blood / M.N. Dworzak, G. Fritsch, P. Buchinger et al // Blood. 1994. — Vol. 83, N2 — P. 415−425.
- Dworzak, M.N. Multiparameter phenotype mapping of normal and post-chemotherapy B lymphopoiesis in pediatric bone marrow / M.N. Dworzak, G. Fritsch, C. Fleisher et al // Leukemia. 1997. — Vol. 11. — P. 1266−1273.
- Dworzak, M.N. Comparative phenotype mapping of normal vs. malignant pediatric B-lymphopoiesis unveils leukemia-associated aberrations / M.N. Dworzak, G. Fritsch, C. Fleischer et al // Exp. Hematol. 1998. — Vol. 26, — P. 305 313.
- Dworzak, M.N. CD99 (MIC2) expression in paediatric B-lineage leukemia/lymphoma reflects maturation-associated patterns of normal Blymphopoiesis / M.N. Dworzak, G. Fritsch, C. Fleischer et al // Br. J. Haematol. -1999. Vol. 105, — P. 690−695.
- Dworzak, M.N. Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia / M.N. Dworzak, G. Froschl, D. Printz et al // Blood. 2002. — Vol. 99, N6. -P. 1952−1958.
- Dworzak, M.N. Flow cytometric detection of minimal residual disease in acute lymphoblastic leukemia / M.N. Dworzak, E.R. Panzer-Grumayer // Leuk. Lymphoma. 2003. — Vol. 44, N9. — P. 1445−1455.
- Dworzak, M.N. Standardization of flow cytometric minimal residual disease evaluation in acute lymphoblastic leukemia: multicentric assessment is feasible / M.N. Dworzak, G. Gaipa, R. Ratei et al // Cytometry B Clin. Cytom. — 2008.-Vol. 74B.-P. 331−340.
- Dworzak, M.N. Modulation of antigen expression in B-cell precursor acute lymphoblastic leukemia during induction therapy is partially transient: evidence for a drug-induced regulatory phenomenon. Results of the AIEOP-BFM-ALL
- FLOW-MRD-Study group / M.N. Dworzak, G. Gaipa, A. Schumich et al // Cytometry B Clin. Cytom.-2010.- Vol. 78B.-P. 147−153.
- Eckert, C. Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukemia / C. Eckert, A. Biondi, K. Seeger et al // Lancet.-2001.-Vol. 358.-P. 1239−1241.
- Escherich, G. Cooperative study group for childhood acute lymphoblastic leukaemia (COALL): long-term results of trials 82, 85, 89, 92 and 97 / G. Escherich, M.A. Horstmann, M. Zimmermann, G.E. Janka-Schaub // Leukemia. -2010. Vol. 24. — P. 298−308.
- Gaipa, G. Drug-induced immunophenotypic modulation in childhood ALL: implications for minimal residual disease detection / G. Gaipa, G. Basso, O. Maglia et al // Leukemia. 2005. — Vol. 18. — P. 703−708.
- Gaipa, G. Reply to van der Sluijs-Gelling et al / G. Gaipa, G. Basso, R. Ratei et al // Leukemia. 2005. — Vol. 19. — P. 2351−2352.
- Gaipa, G. Prednisone induces Immunophenotypic modulation of CD 10 and CD34 in nonapoptotic B-cell precursor acute lymphoblastic leukemia cells / G. Gaipa, G. Basso, S. Aliprandi et al // Cytometry Part B. 2008. — Vol. 74B, — P. 150 155.
- Gaipa, G. Time-point dependent concordance of flow cytometry and RQ-PCR in the MRD detection in childhood ALL: the experience of the AIEOP-BFM-ALL MRD Study Group / G. Gaipa, G. Cazzaniga, M. Veltroni et al // Blood. -2009. Vol. 112, № 11 — P. 260−261.
- Gaynon, P. S. Long-term results of the children’s cancer group studies for childhood acute lymphoblastic leukemia 1983−2002: A Children’s Oncology Group Report / P. S. Gaynon, A.L. Angiolillo, W.L. Carroll et al // Leukemia. 2010. — Vol. 24.-P. 285−297.
- Germano, G. Two consecutive immunophenotypic switches in a child with MZZ-rearranged acute lymphoblastic leukemia / G. Germano, M. Pigazzi, L. del Giudice et al // Haematologica. 2006. — Vol. 91, N2. — P. e29-e31.
- Harbott, J. Incidence of TEL/AML I fusion gene analized consecutively in children with acute lymphoblastic leukemia in relapse / J. Harbott, S. Viehmann, A. Borkhardt et al // Blood. 1997. — Vol. 90, N12. — P. 4933−4937.
- Hilden, J.M. Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children’s Oncology Group / J.M. Hilden, P.A. Dinndorf, S.O. Meerbaum et al // Blood. 2006. — Vol. 108, N2. — P. 441−451.
- Hrusak, O. Antigen expression patterns reflecting genotype of acute leukemia / O. Hrusak, A. Porwit-MacDonald // Leukemia. 2002. — Vol. 16. — P. 1233−1258.
- Hulspas, R. Consideration for the control of background fluorescence in clinical flow cytometry / R. Hulspas, M.R.G. O’Gorman, B.L. Wood et al // Cytometry B Clin. Cytom. 2009. — Vol. 76B. — P. 355−364.
- Imbach, P. Pediatric oncology / P. Imbach, T. Kuhne, R. Arceci. -Heidelberg: Springer, 2006. 267 p.
- Iwamoto, S. Mesenchymal cells regulate the response of acute lymphoblastic leukaemia cells to asparaginase / S. Iwamoto, K. Mihara, J.R. Downing et al//J. Clin. Invest. 2007.-Vol. 117, N4.-P. 1049−1057.
- Jarvik, J.G. The research framework / J.G. Jarvik // Am. J. Roentgenol. — 2001.-Vol. 176.-P. 873−877.
- Jennings, C.D. Recent advances in flow cytometry: application to the diagnosis of hematologic malignancy / C.D. Jennings, K.A. Foon // Blood. — 1997. — Vol. 90, N8.-P. 2863−2892.
- Kamps, W.A. Long-term results of Dutch Childhood Oncology Group studies for children with acute lymphoblastic leukemia from 1984 to 2004 / W.A. Kamps, K.M. van der Pal-de Bruin, A.J.P. Veerman et al // Leukemia. 2010. -Vol. 24.-P. 309−319.
- Karachunskiy, A. Results of the first randomized multicentre trial on childhood acute lymphoblastic leukaemia in Russia / A. Karachunskiy, R. Herold, A. von Stackelberg et al // Leukemia. 2008. — Vol. 22. — P. 1144−1153.
- Kerst, G. Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukemia by flow cytometry and real-time PCR / G.
- Kerst, H. Kreyenberg, C. Roth et al // Br. J. Haematol. 2005. — Vol. 128 — P. 774 782.
- Krampera, M. Flow cytometric detection of minimal residual disease in adult acute lymphoblastic leukaemia / M. Krampera, O. Perbellini, A. Maggioni et al // Haematologica. 2001. — Vol. 86, N3. — P. 322−323.
- Krampera, M. Methodological approach to minimal residual disease detection by flow cytometry in adult B-lineage acute lymphoblastic leukemia / M. Krampera, O. Perbellini, C. Vincenzi et al // Haematologica. 2006. — Vol. 91, N8. -P. 1109−1112.
- Liu, L. Nonpositive terminal deoxynucleotidyl transferase in pediatric precursor B-lymphoblastic leukemia / L. Liu, L. McGavran, M.A. Lovell et al // Am. J. Clin. Pathol. 2004. — Vol. 121,-P. 810−815.
- Lucio, P. Flow cytometric analysis of normal B cell differentiation: a frame of reference for the detection of minimal residual disease in precursor-B-ALL / P. Lucio, A. Parreira, M.V.M. van den Beemd et al // Leukemia. 1999. — Vol. 13. -P. 419−427.
- Lucio, P. BIOMED-I concerted action report: flow cytometric immunophenotyping of precursor B-ALL with standardized triple-stainings / P.1.cio, G. Gaipa, E.G. van Lochem et al // Leukemia. 2001. — Vol. 15. — P. 11 851 192.
- Malec, M. Flow cytometry and allele-specific oligonucleotide PCR are equally effective in detection of minimal residual disease in ALL / M. Malec, E. Bjorklund, S. Soderhall et al. // Leukemia. 2001. — Vol. 15. — P. 716−727.
- Mann, G. Acute lymphoblastic leukemia with t (4-ll) in children 1 year and older: the «big sister» of the infant disease? / G. Mann, G. Cazzaniga, V.H.J, van der Velden et al // Leukemia. 2007. — Vol. 21. — P. 642−646.
- McKenna, R.W. Immunophenotypic analysis of hematogones (B-lymphocyte precursors) in 662 consecutive bone marrow specimens by 4-color flow cytometry / R.W. McKenna, L.T. Washington, D.A. Aquino // Blood. 2001. — Vol. 98, N8.-P. 2498−2507.
- Mejstrikova, E. Detection of residual B precursor lymphoblastic leukemia by uniform gating flow cytometry / E. Mejstrikova, E. Fronkova, T. Kalina et al // Pediatr. Blood Cancer. 2010. — Vol. 54, N1. — P. 62−70.
- Mitchell, C. Long-term follow-up of the United Kingdom medical research council protocols for childhood acute lymphoblastic leukaemia, 1980−2001 / C. Mitchell, S. Richards, C.J. Harrison, T. Eden // Leukemia. 2010. — Vol. 24. — P. 406−418.
- Moppett, J. The clinical relevance of detection of minimal residual disease in childhood acute lymphoblastic leukaemia / J. Moppett, G.A.A. Burke, C.G. Steward et al // J. Clin. Pathol. 2003. — Vol. 56, — P. 249−253.
- Morike, A. Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000 / A. Morike, M. Zimmermann, A. Reiter et al. // Leukemia. 2010. — Vol. 24. -P. 265−284.
- Naeim, F. Hematopathology: morphology, immunophenotype, cytogenetics and molecular approaches / F. Naeim, P.N. Rao, W.W. Crody. -Amsterdam: Elsevier, 2008. 577 p.
- Neudenberger, J. Lack of expression of the chondroitin sulphate proteoglycan neuron-glial antigen 2 on candidate stem cell population in pediatric acute myeloid leukemia / abn (llq23) and lymphoblastic leukemia / t (4-ll) / J.
- Neudenberger, M. Hotfilder, A. Rosemann et al // Br. J. Haematol. 2006. — Vol. 133 — P. 337−344.
- Obuchowski, N.A. ROC analysis / N.A. Obuchowski // Am. J. Roentgenol. 2005. — Vol. 184. — P. 364−372.
- Orfao, A. Flow cytometry: its applications in hematology / A. Orfao, A. Ruiz-Arguelles, F. Lacombe et al // Haematologica. 1995. — Vol. 80, — P. 69−81.
- Paganin, M. Minimal residual disease is an important predictive factor of outcome in children with relapsed «high-risk» acute lymphoblastic leukemia / M. Paganin, M. Zecca, G. Fabbri et al // Leukemia. 2008. — Vol. 22, N12. — P. 21 932 200.
- Pui, C.H. Treatment of acute leukemias / C.IT. Pui. Totowa NJ: Humana Press, 2003. — 580 p.
- Pui, C.H. Toward a total cure for acute lymphoblastic leukemia / C.H. Pui // J. Clin. Oncol. 2009. — Vol. 27, — P. 5121 -5123.
- Pui, C.H. Long-term results of St. Jude Total therapy studies 11, 12, 13A, 13B and 14 for childhood acute lymphoblastic leukemia / C.H. Pui, D. Pei, J.T. Sandlund et al // Leukemia. 2010. — Vol. 24. — P. 371−382.
- Ratei, R. Immunophenotype and clinical characteristics of CD45-negative and CD45-positive childhood acute lymphoblastic leukemia / R. Ratei, C. Sperling, L. Karawajew et al // Ann. Hematol. 1998. — Vol. 77, — P. 107−114.
- Ratei, R. Normal lymphocytes from leukemic samples as an internal control for fluorescence intensity in immunophenotyping of acute leukemias / R. Ratei, L. Karawajew, F. Lacombe et al // Cytometry B Clin. Cytom. 2005. — Vol. 70B.-P. 1−9.
- Rhein, P. CDllb is a therapy-resistant and minimal residual disease-specific in precursor B-cell acute lymphoblastic leukemia / P. Rhein, R. Mitlohner, G. Basso et al // Blood. 2010. — Vol. 115, — P. 3763−3771.
- Salzer, W.L. Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984—2001: a report from the children’s oncology group / W.L. Salzer, M. Devidas, W.L. Carroll // Leukemia. 2010. — Vol. 24.-P. 355−370.
- Schmiegelow, K. Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia / K. Schmiegelow, E. Forestier, M. Hellebostad et al // Leukemia. 2010. — Vol. 24. — P. 345−354.
- Schrappe, M. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90 / M. Schrappe, A. Reiter, W.-D. Ludwig et al. // Blood. 2000. -Vol. 95.-P. 3310−3322.
- Seegmiller, A.C. Characterization of immunophenotypic aberrancies in 200 cases of acute lymphoblastic leukemia / A.C. Seegmiller, S.H. Kroft, N.J. Krandikar, R.W. McKenna // Am J. Clin. Pathol. 2009. — Vol. 132, N6. — P. 692 698.
- Stam, R.W. Towards targeted therapy for infants acute lymphoblastic leukfemia / R.W. Stam, M.L. den Boer, R. Pieters // Brit. J. Haematol. 2006. — Vol. 132,-P. 539−551.
- Stam, R.W. Gene expression profiling-based dissection of MLL translocated and MLL germline acute lymphoblastic leukemia in infants / R.W. Stam, P. Schneider, J.A.P. Hagelstein et al // Blood. 2010. — Vol. 115. — P. 2835−2844.
- Stark, B. Long-term results of the Israeli National Studies in childhood acute lymphoblastic leukemia: INS 84, 89 and 98 / B. Stark, R. Nirel, G. Avrahami et al // Leukemia. 2010. — Vol. 24. — P. 419−424.
- Stary, J. Long-term results of treatment of childhood acute lymphoblastic leukemia in the Czech Republic / J. Stary, Y. Jabali, J. Trka et al // Leukemia. 2010. -Vol. 24.-P. 425−428.
- Stow, P. Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia / P. Stow, L. Key, X. Chen et al // Blood. 2010. — Vol. 115. — P. 4657−4663.
- Szczepanski, T. Why and how to quantify minimal residual disease in acute lymphoblastic leukaemia / T. Szczepanski // Leukemia. 2007. — Vol. 21, — P. 622−626.
- Toedling, J. Automated in-silico detection of cell populations in flow cytometry readouts and it’s application to leukemia disease monitoring / J. Toedling, P. Rhein, R. Ratei et al // BMC Bioinformatics. 2006. — Vol. 7, — P. 282−293.
- Tsuchida, M. Long-term results of Tokyo Children’s Cancer Study Group trials for childhood acute lymphoblastic leukemia, 1984−1999 / M. Tsuchida, A. Ohara, A. Manabe // Leukemia. 2010. — Vol. 24. — P. 383−396.
- Vidriales, M.B. Minimal residual disease monitoring by flow cytometry / M.B. Vidriales, J.F. San-Miguel, A. Orfao et al // Best Pract Res Clin Haematol. -2003.-Vol. 16, N12.-P. 599−612.
- Weinstein, S. Clinical evaluation of diagnostic tests / S. Weinstein, N.A. Obuchowski, M.L. Lieber // Am. J. Roentgenol. 2005. — Vol. 184. — P. 14−19.
- Wuchter, C. Detection of acute leukemia cells with mixed lineage leukemia (MLL) gene rearrangements by flow cytometry using monoclonal antibody 7.1 / C. Wuchter, J. Harbott, C. Schoch et al // Leukemia. 2000. — Vol. 14, — P. 1232−1238.
- Zangrando, A. Validation of NG2 in identifying BP-ALL patients with MLL-rearrangements using qualitative and quantitative flow cytometry: a prospective study / A. Zangrando, F. Intini, G. te Kronie, G. Basso // Leukemia. 2008. — Vol. 22,-P. 858−861.
- Zangrando, A. MLL rearrangements in pediatric acute lymphoblastic and myeloblasts leukemias: MLL specific and lineage-specific signatures / A. Zangrando,
- M. C. Dell’Orto, G. te Kronnie, G. Basso // BMC Med. Genom. 2009. — Vol. 23, -P. 2−36.
- Zweig, M.H. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine / M.H. Zweig, G. Campbell // Clin. Chem.- 1993. -Vol. 31.-P. 561−577.